Bone biologics announces 1-for-8 reverse stock split

Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. the reverse stock split will take effect as of 12:01 a.m. et, on wednesday, december 20, 2023, and shares of bone biologics are expected to trade on a post-split basis on nasdaq under the existing trading symbol, “.
BBLG Ratings Summary
BBLG Quant Ranking